Hepcidin and GDF15 in anemia of multiple myeloma

International Journal of Hematology

Volumn 100, Issue 3, 2014, Pages 266-273

  Mei, Shuchong ^a   Wang, Huaquan ^a   Fu, Rong ^a   Qu, Wen ^a   Xing, Limin ^a   Wang, Guojin ^a   Song, Jia ^a   Liu, Hong ^a   Li, Lijuan ^a   Wang, Xiaoming ^a   Wu, Yuhong ^a   Guan, Jin ^a   Ruan, Erbao ^a   Shao, Zonghong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Anemia; GDF15; Hepcidin; Iron homeostasis; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; FERRITIN; GDF15 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR 15; HAMP PROTEIN, HUMAN; HEMOGLOBIN; HEPCIDIN; MESSENGER RNA; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; BLOOD; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTIPLE MYELOMA; PATHOLOGY; REMISSION;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHRONIC DISEASE; DEXAMETHASONE; FEMALE; FERRITINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBINS; HEPCIDINS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; RNA, MESSENGER;

EID: 84927172597     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1626-7     Document Type: Article

References (31)

1. Robert A, Kyleand S, Rajkumar V, et al. Multiple myeloma. Blood. 2008;111:2962–72.
2. Caravita T, Siniscalchi A, Montanaro M, et al. High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. Int J Hematol. 2009;90:270–2.
3. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia. Med Hypotheses. 2006;66:352–4.
4. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma. 2003;4(Suppl 1):S23–9.
5. Silvestris F, Tucci M, Quatraro C, et al. Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int J Hematol. 2003;78:121–5.
6. Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol. 2007;35:167–72.
7. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–101.
8. Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia–reperfusion. Life Sci. 2006;78:2255–64.
9. Peyssonnaux C, Zinkernagel AS, Datta V, et al. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood. 2006;107:3727–32.
10. Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111:2392–9.
11. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–7.
12. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14:3262–7.
13. Birgegård G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol. 2006;77:378–86.
14. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood. 2003;101:2461–3.
15. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. 2004;113:1271–6.
16. Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol. 2007;139:138–47.
17. Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116:3635–44.
18. Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112:1503–9.
19. Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41:478–81.
20. Andriopoulos B, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482–7.
21. Katodritou E, Ganz T, Terpos E, et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol. 2009;84:524–6.
22. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–9.
23. Tarkun P, Birtas Atesoglu E, Mehtap O, et al. Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients. Acta Haematol. 2013;131:173–8.
24. Corre J, Labat E, Espagnolle N, et al. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 2012;72:1395–406.
25. Tanno T, Lim Y, Wang Q, et al. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2014;123:725–33.
26. Tamary H, Shalev H, Perez-Avraham G. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood. 2008;112:5241–4.
27. Aizawa S, Harada T, Kanbe E, et al. Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity. Exp Hematol. 2005;33:1292–8.
28. Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007;53:284–91.
29. Akiyama M, Okano K, Fukada Y, et al. Macrophage inhibitory cytokine MIC-1 is upregulated by short-wavelength light in cultured normal human dermal fibroblasts. FEBS Lett. 2009;583:933–7.
30. Ago T, Kuroda J, Pain J, et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010;106:1253–64.
31. Léon K, Grace J, Elizabeta N, et al. The erythroid factor erythroferrone and its role in iron homeostasis. Blood. 2013;122:21–4.